Infection and Immunity seminar: Mireia Pelegrin: Vaccine-like effect of antiviral monoclonal antibodies: converting immunotherapies from passive to active

07.11.2017 | Lisbeth Heilesen

Dato tor 23 nov
Tid 10:15 11:00
Sted Lecture room of building 1110 (1110-223)

Dr. Mireia Pelegrin from IGMM, CNRS, Montpellier, FR

“Vaccine-like effect of antiviral monoclonal antibodies: converting immunotherapies from passive to active” 

Antiviral monoclonal antibodies (mAbs) are now recognized as promising tools to fight severe human viral diseases. Thus, understanding the multiple effects of antiviral mAb represents a crucial issue with major therapeutic consequences. Using a murine model of persistent viral infection, we have shown that a short treatment with a highly neutralizing mAb, in addition to blunt viral propagation, can induce a life-long protective immunity by enhancing adaptive humoral and cellular immune responses. We have shown that this immunomodulatory action of the therapeutic mAb depends on its Fc fragment through FcgR-binding effector functions. We have recently identified several cellular and molecular mechanisms involved in the induction of such « vaccine-like » effect upon mAb treatment. These observations might open a new avenue for the design of improved mAb-based antiviral therapies.

Arrangement